These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17473195)

  • 1. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
    Norden-Zfoni A; Desai J; Manola J; Beaudry P; Force J; Maki R; Folkman J; Bello C; Baum C; DePrimo SE; Shalinsky DR; Demetri GD; Heymach JV
    Clin Cancer Res; 2007 May; 13(9):2643-50. PubMed ID: 17473195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
    George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD
    Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
    Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
    J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.
    Ruka W; Rutkowski P; Szawłowski A; Nowecki Z; Debiec-Rychter M; Grzesiakowska U; Dziewirski W; Siedlecki JA; Michej W
    Eur J Surg Oncol; 2009 Jan; 35(1):87-91. PubMed ID: 18289826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].
    Ishikawa T; Kanda T; Kosugi S; Yajima K; Hatakeyama K
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):916-21. PubMed ID: 21677482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.
    Shirao K; Nishida T; Doi T; Komatsu Y; Muro K; Li Y; Ueda E; Ohtsu A
    Invest New Drugs; 2010 Dec; 28(6):866-75. PubMed ID: 19730791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
    Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
    Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
    Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.
    Deprimo SE; Huang X; Blackstein ME; Garrett CR; Harmon CS; Schöffski P; Shah MH; Verweij J; Baum CM; Demetri GD
    Clin Cancer Res; 2009 Sep; 15(18):5869-77. PubMed ID: 19737953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second line therapies for the treatment of gastrointestinal stromal tumor.
    Joensuu H
    Curr Opin Oncol; 2007 Jul; 19(4):353-8. PubMed ID: 17545799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours.
    Zurita AJ; Khajavi M; Wu HK; Tye L; Huang X; Kulke MH; Lenz HJ; Meropol NJ; Carley W; DePrimo SE; Lin E; Wang X; Harmon CS; Heymach JV
    Br J Cancer; 2015 Mar; 112(7):1199-205. PubMed ID: 25756398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib for imatinib-resistant GIST.
    Joensuu H
    Lancet; 2006 Oct; 368(9544):1303-4. PubMed ID: 17046443
    [No Abstract]   [Full Text] [Related]  

  • 14. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
    Motzer RJ; Michaelson MD; Redman BG; Hudes GR; Wilding G; Figlin RA; Ginsberg MS; Kim ST; Baum CM; DePrimo SE; Li JZ; Bello CL; Theuer CP; George DJ; Rini BI
    J Clin Oncol; 2006 Jan; 24(1):16-24. PubMed ID: 16330672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic options in gastrointestinal stromal tumors.
    Stein E; Aranha O; Agulnik M
    Oncology (Williston Park); 2008 Feb; 22(2):206-11; discussion 215-6, 219. PubMed ID: 18409663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
    Harmon CS; DePrimo SE; Raymond E; Cheng AL; Boucher E; Douillard JY; Lim HY; Kim JS; Lechuga MJ; Lanzalone S; Lin X; Faivre S
    J Transl Med; 2011 Jul; 9():120. PubMed ID: 21787417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
    Shen L
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):438-9. PubMed ID: 17845753
    [No Abstract]   [Full Text] [Related]  

  • 19. Gastrointestinal stromal tumour.
    Rubin BP; Heinrich MC; Corless CL
    Lancet; 2007 May; 369(9574):1731-41. PubMed ID: 17512858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
    Polyzos A
    J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):261-6. PubMed ID: 17945482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.